The effect of clonidine on gastrointestinal side effects associated with ultra-rapid opioid detoxification.
Clonidine, an alpha(2)-adrenergic agonist, is used to minimize withdrawal symptoms related to ultra-rapid opioid detoxification procedures. These preliminary data suggest that clonidine possesses dose-related antidiarrheal activity.
Ma
Hong
H
*Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, Texas; Department of Anesthesiology, †Cedars-Sinai Medical Center; and ‡Centinela Hospital Medical Center, Los Angeles, California.
Tang
Jun
J
White
Paul F
PF
Wender
Ronald H
RH
Leverone
Thomas
T
Quon
Rayond
R
Pearce
Scott
S
Chiao
Franklin
F
Erice
Susan
S
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000328:Adult; D003000:Clonidine / Q000627:therapeutic use*; D003967:Diarrhea / Q000209:etiology / Q000517:prevention & control; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D009294:Narcotics / Q000009:adverse effects*; D009325:Nausea / Q000209:etiology / Q000517:prevention & control; D009293:Opioid-Related Disorders / Q000188:drug therapy; D012189:Retrospective Studies; D013375:Substance Withdrawal Syndrome / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control
D000316:Adrenergic alpha-Agonists; D006993:Hypnotics and Sedatives; D009292:Narcotic Antagonists; D009294:Narcotics; D009271:Naltrexone; D003000:Clonidine